PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.66%
Negative revenue growth while AVGO stands at 14.60%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.81%
Negative gross profit growth while AVGO is at 13.49%. Joel Greenblatt would examine cost competitiveness or demand decline.
-18.38%
Negative EBIT growth while AVGO is at 21.43%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-18.60%
Negative operating income growth while AVGO is at 21.43%. Joel Greenblatt would press for urgent turnaround measures.
-18.76%
Negative net income growth while AVGO stands at 21.13%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-17.86%
Negative EPS growth while AVGO is at 21.05%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-17.86%
Negative diluted EPS growth while AVGO is at 21.43%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.91%
Share reduction while AVGO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.81%
Reduced diluted shares while AVGO is at 0.40%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
6.82%
Dividend growth at 50-75% of AVGO's 9.62%. Martin Whitman would question if the firm lags in returning cash to shareholders.
4.17%
OCF growth under 50% of AVGO's 54.74%. Michael Burry might suspect questionable revenue recognition or rising costs.
6.33%
FCF growth under 50% of AVGO's 115.28%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
160.86%
10Y revenue/share CAGR above 1.5x AVGO's 42.47%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
43.38%
5Y revenue/share CAGR similar to AVGO's 42.47%. Walter Schloss might see both companies benefiting from the same mid-term trends.
-7.30%
Negative 3Y CAGR while AVGO stands at 25.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
168.15%
10Y OCF/share CAGR above 1.5x AVGO's 60.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
26.50%
Below 50% of AVGO's 60.47%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
5.20%
Positive 3Y OCF/share CAGR while AVGO is negative. John Neff might see a big short-term edge in operational efficiency.
137.70%
Below 50% of AVGO's 724.55%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
463.32%
5Y net income/share CAGR at 50-75% of AVGO's 724.55%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-41.46%
Negative 3Y CAGR while AVGO is 2.34%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
117.37%
10Y equity/share CAGR at 50-75% of AVGO's 219.27%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
36.69%
Below 50% of AVGO's 219.27%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
11.74%
Below 50% of AVGO's 87.12%. Michael Burry suspects a serious short-term disadvantage in building book value.
2060.94%
Dividend/share CAGR of 2060.94% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
172.72%
Dividend/share CAGR of 172.72% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
129.94%
3Y dividend/share CAGR of 129.94% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-21.06%
Firm’s AR is declining while AVGO shows 14.52%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.29%
Inventory growth well above AVGO's 0.35%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.59%
Negative asset growth while AVGO invests at 6.75%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-1.31%
We have a declining book value while AVGO shows 5.87%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.06%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-5.98%
Our R&D shrinks while AVGO invests at 6.93%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.86%
We cut SG&A while AVGO invests at 5.26%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.